Corgenix Engages Ascendiant Securities for Investment Banking Services
18 Januar 2005 - 5:33PM
PR Newswire (US)
Corgenix Engages Ascendiant Securities for Investment Banking
Services DENVER, Jan. 18 /PRNewswire-FirstCall/ -- Corgenix Medical
Corporation (OTC:CONX) (BULLETIN BOARD: CONX) today announced the
engagement of Ascendiant Securities LLC, an investment banking firm
based in Irvine, California. Ascendiant will explore various
opportunities for the Company on a best efforts basis, including
institutional private placement financing and potential joint
ventures and strategic alliances. Corgenix has chosen Ascendiant
after a comprehensive search within the investment banking
community. In commenting about the new relationship, Douglass
Simpson, Corgenix's president expressed his pleasure in joining
forces with an investment banking firm that has a proven history of
placing institutional investment capital in emerging companies such
as ours. "We want to explore our capital needs with the
institutional marketplace and, for a company such as Corgenix,
management believes that Ascendiant can best leverage their base of
institutional clients." Brad Wilhite, Co-Founder and Managing
Director of Ascendiant Securities stated, "We have closely watched
the development of Corgenix for the past 2 1/2 years and we are
excited about the Company's outlook for growth, not only in its
core business lines, but also in new product areas the Company is
pursuing. We welcome Corgenix as our client and look forward to
assisting the Company with its investment banking needs as we
explore the various opportunities within their growing sector."
About Corgenix Medical Corporation Corgenix is a leader in the
development and manufacturing of anti-Phospholipid test kits, being
the first on the market with an FDA cleared assay for
anti-Cardiolipin (aCL). The Company is based in metropolitan Denver
and is focused on the development of specialized diagnostic kits
for immunology disorders, vascular diseases and bone and joint
disorders. Corgenix diagnostic products are commercialized for use
in clinical laboratories throughout the world. More information is
available at http://www.corgenixonline.com/. About Ascendiant
Securities LLC Ascendiant Securities LLC is a nationally ranked
investment banking firm, registered as a broker-dealer with the
Securities and Exchange Commission (SEC), and a member of the NASD
and SIPC. Ascendiant provides investment banking and corporate
finance services to its emerging public and private clients. These
services include equity private placements of preferred and common
stock, PIPEs (private investments in public equities), direct
participation programs (investment limited partnerships), mezzanine
financing, senior and subordinated debt financing, working capital
facilities, convertible debt, and bridge financing. In December
2004, Ascendiant announced its ranking among the nation's top firms
as recognized by Sagient Research Systems a leading publisher of
independent research for the financial services and institutional
investment communities. Out of 1,050 U.S. firms monitored by
Sagient, Ascendiant Securities tied for 2nd among the most active
placement agents for PIPE financings during the third quarter of
2004. PIPEs have become the funding vehicle of choice for many
emerging technology companies in recent years. More information is
available at http://www.ascendiant.com/. Statements in this press
release that are not strictly historical facts are "forward
looking" statements (identified by the words "believe", "estimate",
"project", "expect" or similar expressions) within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements inherently involve risks and uncertainties that could
cause actual results to differ materially from the forward-looking
statements. Factors that would cause or contribute to such
differences include, but are not limited to, failure to raise the
necessary equity capital, continued acceptance of the Company's
products and services in the marketplace, competitive factors,
changes in the regulatory environment, and other risks detailed in
the Company's periodic report filings with the Securities and
Exchange Commission. The statements in this press release are made
as of today, based upon information currently known to management,
and the company does not undertake any obligation to publicly
update or revise any forward-looking statements. Complete copies of
the Corgenix Medical Corporation Forms 10-KSB and 10- QSB are
available at http://www.sec.gov/. Copies and additional information
can be obtained by contacting William Critchfield, Chief Financial
Officer: phone (303) 453-8903, or e-mail at . DATASOURCE: Corgenix
Medical Corporation CONTACT: William Critchfield, Chief Financial
Officer of Corgenix Medical Corporation, +1-303-453-8903, Web site:
http://www.ascendiant.com/ Web site: http://www.corgenix.com/
Copyright